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Summary
Background.  —  The  zotarolimus-eluting  stent  (ZES)  is  a  new  drug-eluting  stent  that  delivers
zotarolimus,  a  synthetic  analogue  of  sirolimus,  through  a  biocompatible  phosphorylcholine
polymer  coating.  ZES  has  shown  promising  results  compared  with  bare-metal  stents,  but  its
safety and  efﬁcacy  against  sirolimus-eluting  (SES)  and  paclitaxel-eluting  (PES)  stents  is  yet  to
be established.
Aims.  —  We  aimed  to  summarize  current  evidence  from  randomized  trials  comparing  ZES  with
SES and  PES.
Methods.  —  We  searched  the  Medline,  Embase  and  CENTRAL  databases  for  randomized  studies
comparing ZES  with  SES  and  PES  for  percutaneous  coronary  intervention.  Relevant  clinical  and
Abbreviations: CI, conﬁdence interval; DES, drug-eluting stent(s); MACE, major adverse cardiovascular events; OR, odds ratio; PCI, per-
utaneous coronary intervention; PES, paclitaxel -eluting stent(s); RCT, randomized controlled trial; SES, sirolimus-eluting stent(s); STEMI,
T-segment elevation myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; ZES, zotarolimus-
luting stent.
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angiographic  outcomes  were  extracted  and  combined  using  random  and  ﬁxed-effect  models  for
heterogeneous  and  homogenous  outcomes,  respectively.
Results.  —  Seven  randomized  trials  met  the  inclusion  criteria:  ZES  group,  n  =  3787;  SES  group,
n =  2606;  PES  group,  n  =  1966.  Compared  with  SES,  ZES  was  associated  with  signiﬁcantly  higher
odds of  clinically  driven  target  vessel  revascularization  (odds  ratio  [OR]  2.36,  95%  conﬁdence
interval  [CI]  1.78—3.14)  and  target  lesion  revascularization  (OR  2.46,  95%  CI  1.36—4.46).  Com-
pared with  SES,  ZES  had  higher  in-stent  restenosis  (OR  6.13,  95%  CI  3.96—9.50),  late  lumen  loss
‘in-stent’ (mean  difference  [MD]  0.39  mm,  95%  CI  0.34—0.44)  and  late  lumen  loss  ‘in-segment’
(MD 0.18  mm,  95%  CI  0.15—0.21).  ZES  was  associated  with  higher  in-stent  late  lumen  loss  than
PES (MD  0.18  mm,  95%  CI  0.07—0.28).  There  were  no  differences  in  mortality,  reinfarction  or
stent thrombosis  with  ZES  compared  with  SES  and  PES.
Conclusion.  —  ZES  is  not  superior  to  PES  and  is  inferior  to  SES  in  terms  of  angiographic  outcomes
and clinically  driven  revascularization.
©  2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Le  stent  actif  au  zotarolimus  est  un  nouveau  stent  libérant  du  zotarolimus,
analogue synthétique  du  sirolimus,  au  travers  d’un  polymère  biocompatible  (phosphoryl-
choline).  Les  résultats  initiaux  sont  prometteurs  en  comparaison  des  stents  métalliques
mais l’efﬁcacité  et  la  sécurité,  comparativement  aux  stents  au  sirolimus  ou  au  paclitaxel,
n’ont pas  été  établies.  L’objectif  était  donc  de  faire  la  synthèse  des  données  actuelles  des
études randomisées  comparant  ces  trois  types  de  stents  (zotarolimus,  sirolimus  et  pacli-
taxel).
Méthode.  —  Nous  avons  interrogé  les  bases  Medline,  Embase  et  CENTRAL,  en  nous  intéressant
aux études  randomisées  comparant  ces  différents  types  de  stents  pour  les  interventions  coron-
aires percutanées.  Les  données  cliniques  et  angiographiques,  ainsi  que  les  données  évolutives
ont été  extraites  et  associées  en  utilisant  des  modèles  préétablis  (randomisés  et  ﬁxes)  pour
évaluer les  données  évolutives  en  incluant  leur  caractère  homogène  ou  hétérogène.
Résultats.  —  Sept  études  randomisées  répondaient  aux  critères  d’inclusion  incluant
3787 patients  dans  le  groupe  zotarolimus,  2606  patients  dans  le  groupe  sirolimus  et  1966  patients
dans le  groupe  paclitaxel.  Le  groupe  zotarolimus  est  associé  à  un  taux  accru  d’efﬁcacité
sur la  revascularisation  du  vaisseau  site  (OR  2,36,  IC  95  %  1,78—3,14)  et  de  traitement  de
la lésion  cible  (OR  2,46,  IC  95  %  1,36—4,46),  comparativement  aux  stents  au  sirolimus.  Le
stent au  sirolimus  était  associé  à  un  taux  de  resténose  intra-stent  plus  élevé  (OR  6,13,  IC
95 %  3,87—9,50),  une  réduction  de  calibre  intra-stent  (différence  moyenne  0,39  mm,  IC  95  %
0,34—0,44)  ainsi  qu’à  la  réduction  de  calibre  du  segment  considéré  (différence  moyenne
0,18 mm,  IC  95  %  0,15—0,21)  comparativement  aux  stents  au  sirolimus.  Enﬁn,  le  stent  au
zotarolimus  est  associé  avec  une  réduction  de  calibre  intra-stent  plus  élevé  (différence
0,18 mm,  IC  95  %  0,07—0,28)  comparativement  au  paclitaxel.  Il  n’y  avait  pas  de  différence  du
taux de  réinfarctus  ou  de  thrombose  de  stent  avec  le  stent  au  zotarolimus,  comparativement
aux stents  au  sirolimus  ou  au  paclitaxel.
Conclusion.  —  Le  stent  au  zotarolimus  n’est  pas  supérieur  au  stent  au  paclitaxel  et  est  inférieur
en termes  d’efﬁcacité  sur  les  critères  angiographiques  et  l’indication  à  une  revascularisation
sur les  critères  cliniques,  comparativement  au  stent  au  sirolimus.
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weeks  after  implantation  [6].  These  advances  in  stent© 2012  Elsevier  Masson  SAS.
Introduction
The  ﬁrst  commercially  available  drug-eluting  stents  (DES)
—  the  sirolimus-eluting  stent  (SES)  and  the  paclitaxel-eluting
stent  (PES)  —  signiﬁcantly  reduced  rates  of  restenosis  and
repeat  revascularization  after  percutaneous  coronary  inter-
vention  (PCI)  compared  with  bare-metal  stents,  in  a  wide
variety  of  patients  [1].  However,  the  long-term  safety
of  these  stents  has  been  questioned  by  the  reports  of
increased  incidence  of  stent  thrombosis,  especially  with
PES  [2,3]. Arterial  wall  inﬂammation,  delayed  healing  and
poor  endothelialization  are  some  of  the  factors  thought  to
d
r
ms  droits  réservés.
e  responsible  for  late  stent  thrombosis  events  after  DES
mplantation  [4,5].
Zotarolimus  is  a  novel  agent  with  structural  homology
o  sirolimus,  developed  exclusively  for  its  use  in  DES.  The
otarolimus-eluting  stent  (ZES)  has  a  low  proﬁle,  a  thin
trut  design  and  a  biocompatible  phosphorylcholine  polymer
oating  (which  mimics  the  red  blood  cell  outer  membrane),
nd  it  elutes  more  than  90%  of  the  drug  in  the  ﬁrst  fewesign,  polymer  and  drug  elution  kinetics  are  thought  to
educe  platelet  adhesion  and  improve  arterial  healing,  and
ay  therefore  decrease  the  incidence  of  stent  thrombosis
5 A.  Sethi  et  al.
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ompared  with  SES  and  PES.  ZES  has  been  found  to  have
etter  neointimal  strut  coverage  compared  with  SES,  as
easured  by  optical  coherence  tomography  at  9  months
7].  Also,  a  randomized  controlled  trial  (RCT)  comparing
ES  with  a  bare-metal  stent  showed  a  reduction  in  the  rates
f  angiographic  and  clinical  restenosis,  with  no  difference
n  stent  thrombosis  [8].  Despite  early  success,  the  role  of
ES  compared  with  SES  and  PES  is  unclear.  RCTs  comparing
ES  with  SES  and  PES  have  shown  mixed  results.  Therefore,
e  decided  to  perform  a  meta-analysis  of  RCTs  comparing
ES  with  SES  and  PES  for  PCI.
ethods
bjective
ur  goal  was  to  compare  ZES  with  two  established  stents
sed  for  PCI  —  SES  and  PES  —  in  terms  of  angiographic  and
linical  endpoints.
earch strategy
e  performed  a  systematic  search  of  the  Medline,
ochrane  Central  Register  of  Controlled  Trials  (CENTRAL)
nd  Embase  databases  for  RCTs  comparing  ZES  with  SES
nd/or  PES,  published  before  30  September  2010.  The
eywords  ‘zotarolimus’  and  ‘zotarolimus  eluting  stent’
ere  used.  All  retrieved  abstracts  and/or  articles  were
eviewed  for  possible  inclusion.  The  references  of  review
rticles  and  included  studies  were  hand-searched  for  any
elevant  studies.  In  addition;  the  manufacturer’s  website
http://www.medtronic.com/for-healthcare-professionals/
roducts-therapies/cardiovascular/coronary-stents/index.
tm)  was  screened  for  any  potentially  relevant  studies  on
0  September  2010.  No  language  restriction  was  imposed.
CTs  comparing  ZES  with  SES  and/or  PES  and  reporting
ngiographic  and  clinical  endpoints  were  eligible  for  inclu-
ion.  Non-randomized  studies  or  registries;  comparisons
ith  stents  other  than  SES  or  PES  and  studies  reporting  no
linical  or  angiographic  endpoints  were  excluded.
ata extraction and validity assessment
wo  investigators  (A.S.  and  A.B.)  independently  searched
he  databases  for  eligible  studies.  The  original  manuscripts
f  potentially  relevant  studies  were  reviewed.  The  study
haracteristics  and  endpoints  were  entered  on  a  prespe-
iﬁed  data  form.  The  following  study  characteristics  were
xtracted:  sample  size;  method  of  randomization;  inclusion
nd  exclusion  criteria;  mean  age;  use  of  angiographic  follow-
p;  primary  endpoint;  duration  of  dual  antiplatelet  therapy;
ollow-up  duration;  method  of  evaluation  of  angiographic
utcomes;  and  criteria  for  target  vessel  or  lesion  revascu-
arization.  Any  inconsistencies  were  reviewed  with  the  help
f  a  third  author.
ndpointshe  following  clinical  endpoints  were  evaluated:  major
dverse  cardiac  events  (MACE);  mortality;  myocardial
nfarction;  target  vessel  revascularization  (TVR);  target
o
s
i
oigure 1. Study selection process.
esion  revascularization  (TLR);  and  stent  thromboses.  The
ollowing  angiographic  outcomes  were  evaluated:  in-stent
nd  in-segment  restenosis;  and  in-stent  and  in-segment  late
umen  loss.
tatistical analysis
 study-level  analysis  was  done.  Data  were  analysed  using
eview  Manager  5  (The  Nordic  Cochrane  Centre,  The
ochrane  Collaboration,  2008).  Odds  ratios  (ORs)  and  95%
onﬁdence  intervals  (CIs)  were  used  as  summary  statistics
or  all  outcomes  except  the  continuous  variables  in-stent
nd  in-segment  late  lumen  loss,  for  which  mean  differences
ere  calculated.  Studies  were  evaluated  for  heterogene-
ty  by  visual  inspection  of  the  CIs  and  by  means  of  I2
I2 =  (Q—df)/Q],  where  Q  is  the  2 statistic  and  df  is  degree
f  freedom.  A  value  of  I2 >  30%  was  considered  as  an
ndicator  of  signiﬁcant  heterogeneity.  A  Mantel—Haenszel
xed-effect  model  was  used  to  calculate  the  pooled  ORs
or  non-heterogeneous  endpoints.  Random  effect  (DerSimo-
ian)  analysis  was  performed  in  the  presence  of  signiﬁcant
eterogeneity  across  the  studies.  A  P  value  <  0.05  was  con-
idered  signiﬁcant.
esults
even  RCTs  were  included  in  the  meta-analysis  (Fig.  1)
9—15],  resulting  in  a  total  of  8359  patients:  3787  patients
n  the  ZES  group;  2606  in  the  SES  group;  and  1966  in
he  PES  group.  The  characteristics  of  included  studies  are
hown  in  Table  1.  Three  studies  compared  ZES  with  SES,
wo  compared  ZES  with  PES  and  two  compared  all  three
tents.  Three  studies  included  patients  with  elective  PCI
nly,  one  study  included  stable  angina  or  acute  coronary
yndrome  but  excluded  ST-segment  elevation  myocardial
nfarction  (STEMI),  one  study  included  patients  with  STEMI
nly  and  two  included  all-comers  (Table  1).  In  addition,
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Table  1 Characteristics  of  included  studies.
Study Number  of  patients Inclusion  criteria Major  exclusion  criteriaa Mean  age  (years)
ZES SES PES ZES SES PES
ENDEAVOR  III  [11] 323 113 NA Elective  PCI  for  symptomatic
CAD  due  to  native  vessel  lesion
diameter  2.5—3.5  mm  &  length
14—27  mm
Recent  MI  or  PCI;  LVEF  <  30%;
> 40%  lesion  other  than  target
lesion;  unprotected  left  main;
chronic  total  occlusion;  TIMI
ﬂow  grade  <  2
61.4 61.7 NA
ENDEAVOR  IV  [13] 773 NA 775 Clinical  CAD  or  positive
functional  study  with  single  de
novo  lesion  diameter
2.5—3.5  mm  &  length  <  27  mm
Recent  AMI;  LVEF  <  30%;  left
main  or  ostial  lesion
63.5 NA 63.6
ISAR-TEST-2  [9] 339 335 NA Ischaemic  symptoms  or  evidence
of  myocardial  ischaemia  with
>  50%  de  novo  stenosis  in  native
vessels
Left  main  disease;  in-stent
stenosis;  cardiogenic  shock
67.2 66.6 NA
SORT  OUT  III  [15]  1162  1170  NA  Chronic  stable  angina  or  ACS  None  64.3  64.3  NA
ZEST  [14] 883 878 884 Stable  angina  or  ACS  with  ≥  1
lesion
STEMI;  LVEF  <  25%;  shock;  left
main  disease
61.7 61.9 62
ZEST-AMI  [12] 108 110 110 STEMI LVEF  <  30%;  left  main  disease;
previous  MI;  shock
61.9 57.8 59.3
ZoMaxx  I  [10] 199 NA 197 Stable  or  unstable  angina  or
objective  evidence  of  ischaemia
with  lesion  diameter
2.5—3.5  mm  &  length  10—30  mm
Recent  MI;  LVEF  <  30%;  left  main
disease  or  ostial  lesion  within
2  mm
63  NA  63
548
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Table  1 (Continued)
Study  Routine
angiographic
follow  -up
Primary  endpoint  Longest  available
follow  -up  (months)
Stent  type  Duration  of  dual
antiplatelet
therapy  (months)
ZES  SES  PES
ENDEAVOR  III  [11]  8  months  In-segment  late
lumen  loss  at
8 months
36  Endeavor  (Medtronic)  Cypher  (Cordis)  NA  3
ENDEAVOR  IV  [13]  8  months  TVFb at  9  months  24  Endeavor  (Medtronic)  NA  Taxus
Express
(Boston
Scientiﬁc)
6
ISAR-TEST-2  [9]  6—8  months
and  2  years
Binary  restenosis  24  Endeavor  (Medtronic)  Cypher  (Cordis)  NA  12
SORT  OUT  III  [15]  Not  done  MACE  at  9  months  18  Endeavor  (Medtronic)  Cypher  Select/Plus
(Cordis)
NA  12
ZEST  [14] 9  months  MACEc at  12  months  12  Endeavor  (Medtronic)  Cypher  Select  (Cordis)  Taxus
Liberte
(Boston
Scientiﬁc)
12
ZEST-AMI  [12]  8  months  MACE  at  12  months  12  Endeavor  (Medtronic)  Cypher  (Cordis)  Taxus
Liberte
(Boston
Scientiﬁc)
12
ZoMaxx  I  [10]  9  months  In-segment  late
lumen  loss  at
9 months
9  ZoMaxx  (Abbott)  NA  Taxus
Express  2
(Boston
scientiﬁc)
6
ACS: acute coronary syndrome; AMI: acute myocardial infarction; CAD: coronary artery disease; LVEF: left ventricular ejection fraction; MACE: major adverse cardiovascular events; MI:
myocardial infarction; NA: not applicable; PCI: percutaneous coronary intervention; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent; STEMI: ST-segment elevation myocardial
infarction; TIMI: thrombolysis in myocardial infarction; TVF: target vessel failure; TVR: target vessel revascularization; ZES: zotarolimus-eluting stent.
a Only major exclusion criteria are presented here.
b Cardiac death, MI or TVR.
c Death, MI, ischaemia-driven TVR.
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Table  2 Deﬁnitions  of  clinical  endpoints  in  included  studies.
Study MACE Stent  thrombosis  reported
per  Academic  Research
Consortium  [27]
Clinically  or
ischaemia-driven  TVR/TLR
MI
ENDEAVOR  III  [11] Death,  MI  and  clinically
driven  TLR  at  9  months;
and  death,  MI  and  TVR  at
3  years
No,  per  protocol  only Ischaemic  symptoms  or
abnormal  functional  study
with  >  50%  stenosis  or
>  70%  stenosis
Q wave  MI:  q  wave  in  two
or  more  contiguous  leads
with  elevated  CKMB  or  CK
Non  Q  wave:  CK  >  2  times
normal  with  elevated
CKMB
ENDEAVOR  IV  [13] Death,  MI  and  clinically
driven  TLR
Yes  (deﬁnite,  probable
and  possible)
Reported  but  not  deﬁned Not  deﬁned
ISAR-TEST-2  [9] Death,  MI  and  TLR Yes  (deﬁnite,  probable
and  possible)
Clinical  symptoms  or
objective  signs  of
ischaemia
New  Q  waves  and/or  CK  or
CKMB  >  3  times  ULN  in  two
or  more  blood  samples
SORT  OUT  III  [15] Cardiac  death,  MI  and
clinically  driven  TVR
Yes (deﬁnite) No  routine  follow-up
angiography,
revascularization  only  if
indicated  clinically
Universal  deﬁnition  of  MI
per  Thygesen  et  al.  [28]
ZEST  [14]  Death,  MI  and
ischaemia-driven  TVR
Yes  (deﬁnite,  probable
and  possible)
Documented  ischaemia
(symptoms,  ECG  changes
or  functional  study)  with
>  50%  stenosis  or  >  70%
stenosis
New  Q  waves  or  CKMB  >  3
times  ULN
ZEST-AMI  [12] Death,  MI  and
ischaemia-driven  TVR
Yes  (deﬁnite  and  probable) Ischaemic  symptoms  or
functional  study  and  >  50%
stenosis  or  >  70%  stenosis
Symptoms  or  ECG  changes
with  CKMB  > 3  times  ULN
ZoMaxx  [10] Cardiac  death,  MI  and
ischaemia-driven  TVR
Yes  (deﬁnite,  probable
and  possible)
Reported  but  not  deﬁned Q  wave  MI:  q  wave  in  two
or  more  contiguous  leads
with  elevated  CKMB  or  CK
Non  Q  wave:  CK  >  2  times
normal  with  elevated
CKMB
CK: creatine kinase; CKMB: creatine kinase-MB; ECG: electrocardiogram; MACE: major adverse cardiovascular events; MI: myocardial infarction; TLR: target lesion revascularization; TVR:
target vessel revascularization; ULN: upper limit of normal.
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hree  studies  [10,11,13]  had  speciﬁc  angiographic  crite-
ia  for  inclusion,  as  shown  in  Table  1.  The  mean  age  of
he  study  population  varied  from  57  to  67  years.  Patients
roups  were  well  balanced  with  regard  to  the  most  rel-
vant  characteristics  within  individual  studies.  All  studies
xcept  SORT  OUT  III  [15]  had  routine  angiographic  follow-
p.  All  studies  used  the  Endeavor  stent  (Medtronic,  Santa
osa,  CA,  USA)  in  the  ZES  group,  except  for  one  study
10], which  used  the  ZoMaxx  stent  (Abbott  Laboratories,
hicago,  IL,  USA).  The  deﬁnitions  of  the  relevant  clinical
ndpoints  used  in  the  included  studies  are  shown  in  Table  2.
linical  endpoints  were  adjudicated  by  an  independent  com-
ittee  blinded  to  stent  assignment  in  all  seven  studies.
ngiographic  analysis  was  done  at  independent  core  labo-
atories  blinded  to  stent  assignment  in  all  studies.  A  3-year
ollow-up  for  the  ENDEAVOR  III  study  [16]  and  2-year  follow-
p  for  the  ENDEAVOR  IV  [17]  and  ISART-TEST-2  [9]  studies
ere  reported  subsequently,  in  addition  to  the  respective
-month,  12-month  and  12-month  follow-ups  published  ini-
ially.  Also,  the  SORT  OUT  III  trial  reported  clinical  endpoints
t  9  months  and  18  months.  The  other  three  studies  had  a
ollow-up  duration  of  1  year  or  less  (Table  1).  To  accommo-
ate  the  variable  follow-up  periods,  we  decided  to  combine
he  clinical  endpoints  at  follow-up  of  up  to  1  year  and  at
ongest  available  follow-up.  No  signiﬁcant  disagreement  was
ound  between  the  data  retrieved  by  two  investigators.
linical endpoints
ACE
he  deﬁnition  of  MACE  used  in  each  study  is  shown  in  Table  2.
ACE  were  experienced  by  12%,  8.6%  and  11.8%  of  patients
andomized  to  the  ZES,  SES  and  PES  groups,  respectively.
here  was  moderate  heterogeneity  among  the  studies  for
he  endpoint  of  MACE,  as  evidenced  by  the  I2 in  excess  of
0%  for  all  four  comparisons.  Therefore,  a  random-effect
eta-analysis  was  performed.  Compared  with  SES,  ZES  was
ssociated  with  signiﬁcantly  higher  MACE  up  to  1  year  (OR
.50,  95%  CI  1.06—2.13)  and  at  longest  available  follow-up
OR  1.39,  95%  CI  1.01—1.91).  There  was  no  difference  in
ACE  between  PES  and  ZES  up  to  1  year  (OR  0.94,  95%  CI
.67—1.32)  and  at  longest  available  follow-up  (OR  0.94,  95%
I  0.68—1.30).
yocardial  infarction
here  was  no  difference  in  myocardial  infarction  between
ES  versus  SES  (OR  1.0,  95%  CI  0.41—2.45)  and  ZES  versus  PES
OR  0.55,  95%  CI  0.55—1.04)  up  to  1  year  and  at  longest  avail-
ble  follow-up  (ZES  versus  SES:  OR  0.83,  95%  CI  0.40—1.72;
ES  versus  PES:  OR  0.71,  95%  CI  0.48—1.07).
ortality
here  was  no  difference  in  mortality  between  ZES  versus  SES
OR  1.23,  95%  CI  0.80—1.89)  and  ZES  versus  PES  (OR  1.11,  95%
I  0.59—2.06)  up  to  1  year  and  at  longest  available  follow-up
ZES  versus  SES:  OR  1.01,  95%  CI  0.62—1.65;  ZES  versus  PES:
R  1.20,  95%  CI  0.74—1.96).
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linically  driven  target  vessel  and  lesion
evascularization
ll  seven  studies  reported  an  incidence  of  clinically  or
schaemia-driven  TVR  and/or  TLR,  as  deﬁned  in  Table  2.  ZES
as  associated  with  signiﬁcantly  higher  odds  of  clinically
riven  TVR  compared  with  SES  up  to  1  year  (OR  2.31,  95%
I  1.65—3.22)  and  at  longest  available  follow-up  (OR  2.36,
5%  CI  1.78—3.14),  as  shown  in  Fig.  2A.  Similarly,  ZES  use
as  associated  with  signiﬁcantly  higher  odds  of  clinically
riven  TLR  compared  with  SES  up  to  1  year  (OR  2.87,  95%  CI
.89—4.35)  and  at  longest  available  follow-up  (OR  2.46,  95%
I  1.36—4.46),  as  shown  in  Fig.  2B.  There  was  no  difference
n  clinically  driven  TVR  and  TLR  between  ZES  and  PES  up  to
 year  (TVR:  OR  0.85,  95%  CI  0.61—1.18;  TLR:  OR  0.94,  95%
I  0.71—1.26)  and  at  longest  available  follow-up  (TVR:  OR
.88,  95%  CI  0.63—1.23;  TLR:  OR  1.11,  95%  CI  0.58—2.13),
s  shown  in  Fig.  3A  and  B.
tent  thromboses
here  was  no  signiﬁcant  difference  in  stent  thromboses
etween  ZES  and  SES  up  to  1  year  (OR  1.53,  95%  CI
.39—5.96)  and  at  longest  available  follow-up  (OR  1.12,  95%
I  0.41—3.08),  as  shown  in  Fig.  2C.  Similarly,  there  was  no
ifference  in  stent  thromboses  between  ZES  and  PES  up  to
 year  (OR  1.05,  95%  CI  0.56—2)  and  at  longest  available
ollow-up  (OR  0.88,  95%  CI  0.51—1.55),  as  shown  in  Fig.  3C.
ngiographic outcomes
ompared  with  SES,  ZES  was  associated  with  a  signiﬁ-
antly  higher  rate  of  in-stent  restenosis  (OR  6.13,  95%  CI
.96—9.50)  and  in-segment  restenosis  (OR  3.46,  95%  CI
.59—7.50),  as  shown  in  Fig.  4A  and  B,  respectively.  There
as  no  difference  between  ZES  and  PES  in  in-stent  resteno-
is  (OR  1.56,  95%  CI  0.84—2.90)  and  in-segment  restenosis
OR  1.44,  95%  CI  0.88—2.35)  (Fig.  5A  and  B).  Also,  compared
ith  SES,  ZES  was  associated  with  higher  in-stent  late  lumen
oss  (mean  difference  0.39  mm,  95%  CI  0.34—0.44;  Fig.  4C)
nd  in-segment  late  lumen  loss  (mean  difference  0.18  mm,
5%  CI  0.15—0.21).  However,  in-segment  late  lumen  loss  was
imilar  (mean  difference  0.06  mm,  95%  CI  —0.04—0.16)  but
n-stent  lumen  loss  was  higher  (mean  difference  0.18  mm,
5%  CI  0.07—0.28)  in  the  ZES  group  compared  with  the  PES
roup  (Fig.  5C).
iscussion
he  present  meta-analysis  found  that  ZES  use  was  associated
ith  signiﬁcantly  higher  revascularization  rates  compared
ith  SES  use.  Also,  ZES  was  inferior  to  SES  in  terms  of  the
ngiographic  endpoints  of  restenosis  and  late  lumen  loss.
ES  was  similar  to  PES  for  all  clinical  and  most  angiographic
ndpoints,  except  in-stent  late  lumen  loss.  In  addition,  no
ifference  in  stent  thromboses  was  apparent  during  follow-
p  when  ZES  was  compared  with  SES  and  PES.  To  the  best  of
ur  knowledge,  this  is  the  ﬁrst  meta-analysis  comparing  ZES
irectly  with  SES  and  PES  separately.  The  included  studies
aried  in  terms  of  patient  population,  ranging  from  stable
oronary  artery  disease  to  acute  coronary  syndrome,  STEMI
nd  all-comers,  a  pattern  that  represents  the  state  of  DES
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aFigure 2. Forest plots comparing the zotarolimus-eluting stent (
(A) target vessel revascularization; (B) target lesion revascularizatio
use  in  contemporary  practice  (Table  1).  We  combined  these
studies  to  achieve  a  higher  power  to  evaluate  ZES  (a  rela-
tively  new  DES),  against  established  DESs  (SES  and  PES),  in
terms  of  both  clinical  and  angiographic  endpoints.
Zotarolimus  is  an  analogue  of  sirolimus,  which  binds  to
the  immunophillin  protein  FKBP  12  to  inhibit  a  growth-
regulating  enzyme  known  as  mammalian  target  of  rapamycin
(mTOR)  [18]. Zotarolimus  has  a  shorter  half-life  and  less
afﬁnity  for  FKBP  12  than  sirolimus.  In  addition,  the  two
ZES  evaluated  in  our  analysis  —  Endeavor  (Medtronic,  Santa
t
a
s
awith the sirolimus-eluting stent (SES) for the following endpoints:
) stent thrombosis. CI: conﬁdence interval; M-H: Mantel—Haenszel.
osa,  CA,  USA)  and  ZoMaxx  (Abbott  Laboratories,  Chicago,
L,  USA)  —  have  rapid  drug  elution  kinetics,  a  clear  dis-
inction  from  currently  available  SES,  which  have  a  slower
rug  release  [18]. These  pharmacological  differences  may
xplain  the  relatively  weak  antiproliferative  effect  of  ZES
nd  consequently  higher  restenosis  compared  with  SES.  On
he  other  hand,  ZES  was  similar  to  PES  with  regard  to  most
ngiographic  endpoints,  which  is  consistent  with  previous
tudies  [19,20]  that  showed  a  higher  incidence  of  clinical
nd  angiographic  stenosis  with  PES  compared  with  SES.  The
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(igure 3. Forest plots comparing the zotarolimus-eluting stent (Z
A) target vessel revascularization; (B) target lesion revascularizatio
ifference  in  late  lumen  loss  between  SES  and  ZES  was
igher  than  reported  previously  between  SES  and  PES  [20].
s  some  authors  have  suggested  a  curvilinear  relationship
etween  late  lumen  loss  and  probability  of  TLR  [21], this
ccentuated  late  lumen  loss  may  place  patients  treated  with
ES  closer  to  the  steeper  slope  of  the  curve.  Although  the
oMaxx  and  Endeavor  stents  have  a  similar  thin  strut  design,
iocompatible  phosphorylcholine  polymer  and  zotarolimus
oncentration  (10  g/mm),  there  are  some  differences  in
he  stent  platforms  and  drug  elution  kinetics  [18]. Exclusion
f  the  ZoMaxx  I  study  from  the  meta-analysis  did  not  change
he  results  for  any  endpoint  signiﬁcantly.
a
b
w
Iith the paclitaxel-eluting stent (PES) for the following endpoints:
) stent thrombosis. CI: conﬁdence interval; M-H: Mantel—Haenszel.
All studies  except  the  SORT  OUT  III  study  had  a  rou-
ine  angiographic  follow-up  (Table  1),  which  raises  concern
bout  increased  revascularization  rates  secondary  to  ocu-
ostenotic  reﬂex.  All  included  studies  reported  clinically  or
schaemia-driven  revascularization  rates.  In  addition,  stud-
es  comparing  ZES  with  SES  reported  explicit  indications
sed  for  clinically  or  ischaemia-driven  revascularization
Table  2).  Although  more  than  70%  stenosis  on  follow-up
ngiogram  was  considered  as  one  of  the  indication  for  TLR,
ut  TLR  in  the  ZES  group  in  the  SORT  OUT  III  study  (6.1%),
hich  had  no  angiographic  follow-up,  and  in  the  ENDEAVOR
II  (6.3%)  and  ZEST  (4.8%)  studies,  which  had  planned
ZES  compared  with  SES  and  PES  in  PCI  553
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pFigure 4. Forest plots comparing the zotarolimus-eluting stent (Z
in-segment restenosis; (C) in-segment late lumen loss. CI: conﬁden
angiographic  follow-up,  were  not  signiﬁcantly  different.  On
the  other  hand,  TLR  in  the  ISAR-TEST-2  study  was  higher
in  both  the  ZES  (14%)  and  SES  (10.7%)  groups.  All  statisti-
cal  heterogeneity  in  the  analysis  for  TLR  was  explained  by
the  ISAR-TEST-2  study;  its  exclusion  reduced  I2 from  74%  to
0%  without  loss  of  statistical  signiﬁcance  (OR  3.43,  95%  CI
2.36—4.98).  Therefore,  the  impact  of  routine  angiographic
follow-up  of  revascularization  rates  cannot  be  clearly  deter-
mined  from  our  analysis.  However,  the  results  of  TLR  for
t
(
n
(ith the sirolimus-eluting stent (SES) for: (A) in-stent restenosis; (B)
erval; M-H: Mantel—Haenszel.
ES versus  SES  were  robust,  and  remain  signiﬁcant  on
xclusion  of  one  study  at  a  time  from  the  meta-analysis.
lso,  the  odds  of  in-stent  restenosis  were  lower  in  the
NDEAVOR  III  study  (4.67),  which  systematically  excluded
atients  with  complex  lesions  or  acute  coronary  syndrome,
han  in  the  SORT  OUT  III  (6.38),  ZEST  (5.86)  and  ZEST-AMI
13.66)  studies,  which  included  patients  with  acute  coro-
ary  syndrome  and  had  no  angiographic  exclusion  criteria
Fig.  4).  Moreover,  both  the  ZEST  and  SORT  OUT  III  trials
554  A.  Sethi  et  al.
F ZES) 
( dence
i
w
g
e
t
i
P
w
m
f
m
[
oigure 5. Forest plots comparing the zotarolimus-eluting stent (
B) in-segment restenosis; (C) in-segment late lumen loss. CI: conﬁ
ndependently  found  a  signiﬁcant  increase  in  TVR  and  TLR
ith  ZES  use.  Therefore,  it  is  possible  that  clinical  and  angio-
raphic  differences  between  ZES  and  SES  will  become  appar-
nt  in  high-risk  patients  in  the  real-world  clinical  setting.
ZES  was  designed  with  the  intention  of  reducing  stent
hrombosis  compared  with  SES  and  PES.  The  cumulative
ncidence  of  stent  thrombosis  in  the  ENDEAVOR  I—IV  and
K  studies  at  5  years  was  about  0.8%  (95%  CI  0.06—1.54),
hich  is  lower  than  the  cumulative  incidence  of  1%  in  our
g
i
(
vwith the paclitaxel-eluting stent (PES) for: (A) in-stent restenosis;
 interval; M-H: Mantel—Haenszel.
eta-analysis,  considering  the  difference  in  duration  of
ollow-up  [21]. This  could  be  due  to  the  inclusion  of  acute
yocardial  infarction  and  complex  lesions  in  the  studies
9,14,15],  which  contributed  the  majority  of  patients  to
ur  analysis,  compared  with  elective  PCI  for  a  single  angio-
raphically  deﬁned  lesion  in  the  ENDEAVOR  I—IV  studies.  The
ncidence  of  stent  thromboses  in  the  SES  (0.8%)  and  PES
1.3%)  cohorts  in  our  analysis  were  similar  to  those  in  pre-
ious  studies  [22,23].  It  is  important  to  note  that  only  the
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[ZES  compared  with  SES  and  PES  in  PCI  
ENDEAVOR  III  [16], ENDEAVOR  IV  [17]  and  ISAR-TEST-2  [9]
trials  reported  the  incidence  of  stent  thromboses  later  than
6  months  after  completion  of  the  recommended  duration  of
dual  antiplatelet  therapy,  at  follow-up  periods  of  3  years,
2  years  and  2  years,  respectively  (Table  1).  Although  there
was  no  difference  in  very  late  stent  thromboses  between  ZES
and  SES  in  the  ENDEAVOR  III  and  ISAR-TEST-2  studies,  a  trend
(P  =  0.069)  towards  higher  very  late  stent  thromboses  with
PES  compared  with  ZES  was  seen  in  the  ENDEAVOR  IV  trial.
The  results  of  the  PROTECT  trial  —  a  large  randomized-
design  trial  comparing  ZES  with  SES  for  the  primary  endpoint
of  stent  thromboses  at  3  years  — recently  became  available
[24]. Considering  the  magnitude  and  relevance  of  this  study,
we  performed  an  updated  analysis.  The  addition  of  the  PRO-
TECT  trial  further  strengthened  our  conclusions,  as  there
was  no  difference  in  mortality  (OR,  1.03,  95%  CI  0.75—1.41),
myocardial  infarction  (OR  0.93,  95%  CI  0.63—1.38)  or  stent
thrombosis  (OR  1.06,  95%  CI  0.57—1.97)  between  ZES  and
SES.  However,  ZES  was  associated  with  a  higher  incidence
of  TVR  (OR  1.87,  95%  CI  1.13—3.08)  and  TLR  (OR  2.18,  95%
CI  1.44—3.31).  The  forest  plots  are  shown  in  Figs.  S1  and  S2,
respectively,  in  the  supplementary  appendix.
To  decrease  the  incidence  of  stent  thrombosis  while
maintaining  the  beneﬁt  of  low  repeat  revascularization  is
one  of  the  key  objectives  of  current  research  into  stent
design  and  development  [25]. As  opposed  to  TLR,  the  inci-
dence  of  stent  thrombosis  is  very  low  in  contemporary
clinical  studies  examining  the  newer  stents.  Therefore,  a
very  large  sample  size  with  a  long  follow-up  period  is
needed  to  detect  any  statistically  signiﬁcant  difference
compared  with  established  stents.  Also,  the  SES  (Cypher;
Cordis/Johnson  and  Johnson,  FL,  USA),  which  remains  unsur-
passed  in  terms  of  TLR  and  restenosis,  will  be  no  longer
manufactured  by  the  end  of  2011.  These  limitations  pose
a  challenge  to  the  design  and  conduct  of  clinical  trials  eval-
uating  the  newer  coronary  stents.
Study limitations
This  was  a  study-level  analysis;  patient-level  data  may
improve  the  accuracy  of  the  results.  Owing  to  the  small
number  of  studies  in  our  analysis,  no  formal  test  to  detect
publication  bias  was  done.  As  long-term  follow-up  was  not
available  for  most  studies,  no  robust  conclusion  can  be
drawn  about  the  difference  in  very  late  stent  thrombo-
sis,  particularly  after  the  completion  of  dual  antiplatelet
therapy.  Also  of  note,  these  results  are  not  applicable  to
the  newer  generation  ZES  (Endeavor  Resolute),  which  has  a
different  polymer  and  drug  elution  kinetics  [17]. A  recent
observational  study  with  the  Resolute  ZES  found  a  very  low
rate  of  clinical  restenosis  compared  with  historical  Endeavor
ZES  data  [26].
Conclusion
ZES  appears  inferior  to  SES  and  similar  to  PES  in  terms  of
angiographic  outcomes  and  revascularization  rates.  Mortal-
ity  and  reinfarction  were  similar  when  ZES  was  compared
with  SES  and  PES.  Also,  no  difference  in  stent  thromboses
was  apparent  in  studies  with  follow-up  periods  ranging  from
1  to  3  years.
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